HCRU in Invasive Candidiasis: Healthcare Practitioner Survey

  • Research type

    Research Study

  • Full title

    Healthcare Resource Use in Invasive Candidiasis: Healthcare Practitioner Survey

  • IRAS ID

    357819

  • Contact name

    David Enoch

  • Contact email

    david.enoch@nhs.net

  • Sponsor organisation

    Mundipharma Research Limited

  • Duration of Study in the UK

    0 years, 4 months, 31 days

  • Research summary

    This study looks at how much time and hospital resources are used when treating invasive candidiasis, a serious fungal infection, with different types of antifungal medications called echinocandins. Normally, echinocandins are given once a day for at least 14 days. However, a newer treatment called rezafungin only needs to be given once a week, which may reduce how much hospital time and equipment are needed. This research is being commissioned by the manufacturer of rezafungin.

    To understand the difference in time and resources used between once-daily and once-weekly echinocandin treatment, nurses from hospitals in the UK, Spain and Germany will take part in a survey. These nurses already care for patients with invasive candidiasis and are experienced in giving these medications. Each time they give a dose of an echinocandin to a patient in their care, they will fill out a short survey that will take about 10 minutes, to record how long the process takes and the materials used. The study will not collect any patient names or personal details, so the patient stays anonymous. The goal is to collect at least 63 survey responses for once-daily echinocandin treatment and 63 responses for once-weekly rezafungin treatment. Nurses may fill in the survey more than once, depending on how often they administer these treatments. The responses will be summarised for each treatment group using descriptive statistics.

    The results will provide valuable real-world evidence for hospitals, health services and decision-makers, helping to guide efficient use of healthcare staff and improve planning for patient care. The study does not involve any changes to patient treatment or additional risks to patients. The burden on nurse participants is minimal, involving only the completion of a short survey after performing a task they already do as part of their usual role.

  • REC name

    East Midlands - Nottingham 1 Research Ethics Committee

  • REC reference

    25/EM/0276

  • Date of REC Opinion

    3 Dec 2025

  • REC opinion

    Favourable Opinion